A case of uterine cervical carcinosarcoma recurrence who obtained a clinically complete response by ifosfamide, doxorubicin and cisplatin

Cervical carcinosarcoma (CS) is a rare gynecologic tumor. The histogenesis, clinical features, and optimal treatment remain unclear. We report a case of cervical CS recurrence to the right lung, which had complete response by treating with ifosfamide, doxorubicin and cisplatin (IAP). A 61-year-old woman underwent semi-radical hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymphadenectomy for CS of the uterine cervix. Eleven months later, the patient presented with left pulmonary metastasis. She refused debulking surgery and had chemotherapy with IAP. After four cycles of chemotherapy, the metastatic tumor completely disappeared. Unfortunately, a re-recurrent tumor was seen in the same lung area six months after IAP. Eventually, she died 39 months after surgery.

Uterine cervix; Carcinosarcoma; Recurrence; Chemotherapy; Clinically complete response

[1] Abell M., Ramirez J.A.: “Sarcomas and carcinosarcomas of the uterine cervix”. Cancer, 1973, 31, 1176.

[2] Ferriera H.P.: “A case of mixed mesodermal tumor of the uterine cervix”. J. Obstet. Gynaecol. Br. Emp., 1951, 58, 446.

[3] Wright J.D., Rosenblum K., Huettner P.C., Mutch D.G., Rader

J. S., Powell M.A. et al.: “Cervical sarcomas: an analysis of incidence and outcome”. Gynecol. Oncol., 2005, 99, 348.

[4] Pazdur R., Cioa L.R., Hoskins W.J., Wagman L.D.: “Cancer management: a multidisciplinary approach”. In: Barakat R.R., Greven K., Markman M., Thigpen J.T. (eds.). Endometrial Cancer, 2001, 389.

[5] Clement P.B., Zubovits J.T., Young R.H., Scully R.E.: “Malignant mullerian mixed tumors of the uterine cervix: a report of nine cases of a neoplasm with morphology often different from its counterpart in the corpus”. Int. J. Gynecol. Pathol., 1998, 17, 211.

[6] Rotmensch J., Rosenhein N.B., Woodruff J.D.: “Cervical sarcoma: a review”. Obstet. Gynecol. Sur., 1983, 38, 456.

[7] Peters W.A., Kumar N.B., Fleming W.P., Morley G.W.: “Prognostic features of sarcomas and mixed tumors of the endometrium”. Obstet. Gynecol., 1984, 63, 550.

[8] Hajnal-Papp R., Szilagyi I.: “Malignant mullerian tumours of the uterus”. Arch. Gynecol. Obstet., 1988, 241, 209.

[9] Le T.: “Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population”. Eur. J. Surg. Oncol., 2001, 27, 282.

[10] Chi D.S., Mychalczak B., Saigo P.E., Rescigno J., Brown C.L.: “The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma”. Gynecol. Oncol., 1997, 65, 493.

[11] Major F.J., Blessing J.A., Silverberg S.G., Morrow C.P., Creasman

W. T., Currie J.L. et al.: “Prognostic factors in early-stage uterine sarcoma: a gynecologic oncology group study”. Cancer, 1993, 71, 1702.

[12] Thigpen J.T., Blessing J.A., Orr J.W. Jr., DiSaia P.J.: “Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group study”. Cancer Treat. Rep., 1986, 70, 271.

[13] Thigpen J.T., Blessing J.A., Beecham J., Homesley H., Yordan E.: “Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study”. J. Clin.Oncol., 1991, 9, 1962.

[14] Sutton G.P., Blessing J.A., Rosenshein N., Photopulos G., DiSaia P. J.: “Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study)”. Am. J. Obstet. Gynecol., 1989, 161, 309.

[15] Sutton G.P., Blessing J.A., Homesley H.D., Malfetano J.H.: “A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinumbased chemotherapy: a Gynecologic Oncology Group study”. Gynecol. Oncol., 1994, 53, 24.

[16] Curtin J.P., Blessing J.A., Soper J.T., DeGeest K.: “Paclitaxel in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study”. Gynecol. Oncol., 2001, 83, 268.

[17] van Rijswijk R.E., Vermorken J.B., Reed N., Favalli G., Mendiola C., Zanaboni F. et al.: “Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment ofCancer Gynecological Cancer Group (EORTC 55923)”. Eur. J. Cancer, 2003, 39, 481.

[18] Omura G.A., Major F.J., Blessing J.A., Sedlacek T.V., Thigpen J. T., Creasman W.T. et al.: “A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas”. Cancer, 1983, 52, 626.

[19] Gershenson D.M., Kavanagh J.J., Copeland L.J., Edwards C.L., Stringer C.A., Wharton J.T.: “Cisplatin therapy for disseminatedmixed mesodermal sarcoma of the uterus”. J. Clin. Oncol., 1987, 5, 618.

[20] Sutton G.P., Blessing J.A., Barrett R.J., McGehee R.: “A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group Study”. Gynecol. Oncol., 2000, 79, 147.